Many other MNKs inhibitors have shown promising antitumor effects in prostate cancer models such as 3-azido withaferin A [140], a dual modulator of Ras/MNK and PI3K/AKT/mTOR pathways, 2′H-spiro[cyclohexane-1,3′-imidazo[1 ,5-a] pyridine]-1′,5′-dione derivatives [98] and eFT508, currently in phase II trials for patients with advanced CRPC (Table 2). Here, ATP7A is linked to prostate carcinoma.